Navigation Links
MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness

WASHINGTON, May 4, 2011 /PRNewswire-USNewswire/ -- The Center for Best Practices, a new affiliate organization of Medicaid Health Plans of America (MHPA), today announced the receipt of financial sponsorship from Raritan, NJ-based pharmaceutical company Ortho-McNeil-Janssen Pharmaceuticals, Inc. to engage Medicaid managed care clinical leadership on the best ways to treat plan members with schizophrenia, bipolar disorder, and other severe mental illness (SMI).  The initiative called "Best Practices to Integrate Care for Seriously Mentally Ill Beneficiaries" will begin immediately and will take a multifaceted approach to raising the level of understanding at Medicaid health plans including creating web-based educational programs and publishing resources to aid in management of SMI.

"The mission of the Center for Best Practices is to inform and educate Medicaid health plans on how best to treat the low-income population they serve, with some of the Center's priorities falling very much in line with the goals of this effort," said Thomas L. Johnson, MHPA's President and CEO.  "The Center's focus on highlighting effective Medicaid health plan programs and improving care coordination and treatment adherence, especially in the area of medical and behavioral health services, dovetails well with the commitment of Ortho-McNeil-Janssen to improving the health of patients affected by these diseases. We are proud to have such a dedicated and innovative company that has done so much in the field of mental health as the Center's first-ever sponsor."

The Center will provide web content and resources such as data and information for effectively serving those Medicaid patients with SMI.  The Center also will partner with advocacy groups representing the SMI population to better understand the issues specific to this disease.  Educational webinars on topics ranging from increasing adherence to ensuring effective transitions from inpatient to outpatient care are also planned.  In addition, the Center will publish a compilation of health plan best practices that details specific examples of progress in treating those with SMI. This compendium will also include statistics and other mental health resources that may be useful to Medicaid health plans.

"People with life-altering diseases such as schizophrenia or bipolar disorder often experience a number of issues including higher rates of unemployment, poverty and even homelessness," Johnson noted. "Coordinated care to address the physical and mental health needs of this special population is needed.  Given the integrated systems of care inherent in Medicaid health plans, disseminating knowledge of what works best for those with serious mental illness is a very important step in ensuring the best possible care for these patients."

Ortho-McNeil-Janssen Pharmaceuticals, Inc. is the first pharmaceutical company sponsor for this project. The sponsorship will ultimately be expanded to include multiple pharmaceutical company sponsors, however sponsors will have no control or influence on initiatives conducted by the MPHA Center for Best Practices.

About Medicaid Health Plans of America

Medicaid Health Plans of America (MHPA) is the leading trade association solely focused on representing Medicaid health plans. MHPA provides advocacy, research and organized forums that support the development of policy solutions to enhance the delivery of quality health care. For more information, visit Medicaid Health Plans of America at or email at

Media Contact:
Joe Reblando

SOURCE Medicaid Health Plans of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
6. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
(Date:11/30/2015)...  QT Vascular Ltd., together with its subsidiaries (the ... TriReme Medical LLC and Quattro Vascular Pte. Ltd., collectively ... assembly and distribution of advanced therapeutic solutions for the ... announce that a three-judge panel of the ... Federal Circuit ("Federal Circuit") has unanimously granted the Group ...
(Date:11/30/2015)... ) has ... Market 2015-2019" report to their offering. ... of the "Orphan Drugs Market 2015-2019" ... and Markets ( ) has announced the ... report to their offering. ...
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... companies, announced today that it has officially launched a sleek, mobile-ready and user-centric ... that his company’s new website clearly outlines the benefits that its SEO services ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Christina Colon as a 2015-2016 inductee into its ... for leadership in pharmacy. NAPW is the nation’s leading networking organization exclusively for ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection or even a need ... tumors? , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital ... point to tumors. , “Bad headaches that don’t go away, that don’t ...
(Date:11/30/2015)... ... ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from INDE Broadcast ... collection of interactive exhibits within the Kids In Charge! building. In collaboration with the ... closer than ever to a range of animals as they drink, sleep and play ...
Breaking Medicine News(10 mins):